Arvelle Therapeutics Licenses Exclusive Development & Commercialization Rights for Cenobamate from SK Biopharmaceuticals in EU

 Arvelle Therapeutics Licenses Exclusive Development &  Commercialization Rights for Cenobamate from SK Biopharmaceuticals in EU

Arvelle Therapeutics Licenses Exclusive Development & Commercialization Rights for Cenobamate from SK Biopharmaceuticals in EU


Shots:

  • SK Biopharmaceuticals to receive $100M upfront, $430M milestones, and royalties on sales of product. Arvelle to get exclusive rights to develop and commercialize SK’s Cenobamate in EU
  • SK also has an option to make equity investment in Arvelle and will retain WW commercialization rights for Cenobamate (Ex-EU). Arvelle plans to file Cenobamate’s MAA to EU based on the trial conducted by SK, for partial-onset seizures in adults 
  • Cenobamate (YKP3089) is an antiepileptic drug involved in modulating GABA-A receptor and has received NDA approval from the US FDA for partial-onset seizures in adults in Feb, 2019

Click here to read full press release/ article | Ref: GlobeNewwire | Image:  Twitter

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post